HealthCare Global Q4 FY26 PAT falls 70% to ₹2.17 cr

Why HealthCare Global’s Q4 numbers matter

HealthCare Global Enterprises (HCG) reported a steep fall in consolidated profitability for the March 2026 quarter even as revenue increased year-on-year. The company’s disclosures in the shared data show higher operating costs and an exceptional charge during the quarter. For investors tracking hospital operators, the quarter highlights how margin pressure can persist despite top-line growth, particularly when depreciation, interest, and one-off items rise after expansion and acquisitions.

Q4 FY26: Consolidated profit drops despite revenue growth

For Q4 FY26, HCG reported a 70.5% year-on-year decline in consolidated net profit to ₹2.17 crore. Over the same period, revenue rose 11.5% year-on-year to ₹650.29 crore. The company also reported profit before tax (PBT) of ₹1.25 crore for Q4 FY26, down 90.8% from ₹13.62 crore in Q4 FY25. The combination of higher expenses and exceptional items stands out in the quarter’s profit bridge.

Operating costs rise and exceptional charge hits Q4 FY26

HCG’s total operating expenditure in Q4 FY26 was ₹559.16 crore, up 16.6% year-on-year, according to the figures provided. The company also recorded an exceptional charge of ₹31.91 crore in the March 2026 quarter. While revenue expanded year-on-year, the cost increase outpaced revenue growth in the same period, which typically pressures operating leverage. With the exceptional charge added on top, reported profitability for the quarter weakened sharply.

FY26: Profit declines even as revenue grows

For the full year FY26, HCG recorded consolidated net profit of ₹13.76 crore, a decline of 69% year-on-year. Revenue from operations for FY26 rose 14.4% year-on-year to ₹2,538.43 crore. The article also cites the prior year’s FY25 net profit at ₹44.41 crore, providing the year-on-year comparison used for the decline. The full-year pattern mirrors the quarter: stronger revenue growth alongside significantly weaker bottom-line outcomes.

Another set of quarterly metrics in the shared data

The provided text also includes a separate quarterly snapshot for the quarter ended March 2026 that differs from the consolidated Q4 FY26 numbers above. In that snapshot, revenue is shown at ₹613.16 crore, a quarter-on-quarter increase of 4.79% from ₹585.16 crore. Operating profit is listed at ₹52.98 crore, down 2.61% quarter-on-quarter from ₹54.40 crore, and stated as 24.60% higher year-on-year. The same snapshot reports PBDT at ₹63.85 crore, down 1.65% quarter-on-quarter from ₹64.92 crore, and PBT at ₹11.92 crore, down 12.48% quarter-on-quarter from ₹13.62 crore.

Net profit figures vary across the disclosed summaries

In the same alternate snapshot, net profit is shown at ₹4.75 crore for the quarter ended March 2026, down 35.46% quarter-on-quarter from ₹7.36 crore, and down 60.68% year-on-year. Separately, the consolidated comparison in the article states net profit declined to ₹2.17 crore in the March 2026 quarter from ₹7.36 crore in the March 2025 quarter. Since these values are presented side-by-side in the supplied text without clarification, readers should note that the article contains multiple profit and revenue series for the same period.

FY25 and FY24 context from earlier disclosures

The data included in the text also references HCG’s earlier announced results for FY24 and Q4 FY24 in INR million, which have been converted here to ₹ crore for consistency. For Q4 FY24, income from operations was reported at 4,946 million, which is ₹494.60 crore, and PAT at 213 million, which is ₹21.30 crore. For Q4 FY25, another release excerpt in the text states revenue of 5,585.1 million, which is ₹558.51 crore, with PAT of 74 million, which is ₹7.40 crore, and a PAT margin of 1.3% (versus 4.3% in the comparable quarter).

Profit pressure linked to depreciation and interest costs

The text also attributes lower PAT to “higher depreciation and interest expense from growth investments and acquisitions undertaken in the last year.” This explanation is consistent with what investors often see when hospital networks expand capacity or add centres through acquisition: depreciation rises as assets are capitalised, while finance costs increase if growth is funded through debt. In such periods, revenue growth can remain healthy while reported profit lags.

Key financial snapshot from the provided data

The table below summarises the main figures explicitly stated in the text. All amounts are in ₹ crore.

Market impact and what investors typically track next

From the data provided, the immediate market takeaway is that profit contracted sharply even though revenue grew, indicating pressure from costs and exceptional items. For investors, the next focus areas usually include whether exceptional charges recur, and whether operating expenditure growth moderates relative to revenue. The text also shows that quarter-on-quarter movements are being tracked (revenue, operating profit, PBDT, PBT, and net profit), suggesting that near-term trends in margins and finance costs remain central to the story.

Conclusion

HCG’s reported Q4 FY26 performance shows a large year-on-year decline in profit, alongside double-digit revenue growth and a stated exceptional charge in the quarter. For FY26, revenue increased while net profit fell sharply versus FY25. Future updates that reconcile the multiple quarterly series presented in the shared data, and detail the drivers of cost and exceptional items, will be important for investors following earnings quality and profitability.